On the 5th of March, our company Monitoring Life had the honor of participating in the Innovation Catalyst Days to showcase the work of PCM in promoting startups. PCM's CEO, Marta Del Castillo Vázquez, moderated the round table "Innovation Catalyst: Empowering Deep Tech," featuring three startups/scaleups from PCM that have found the Park to be a key ally in bringing their technologies to market.
During the event, we gained valuable insights into how these technologies are evolving, the impact of AI, and the challenges they face. The discussion included contributions from César Martínez, CEO of Unmanned Teknologies Applications S.L. (UTEK), in the USV sector; Esmeralda Zefi, Marketing Director of Monitoring Life, in the medical devices sector; and Daniel González Muñoz, CEO of the CSIC spinoff Nanostine, in the fields of nanotechnology and nanocoatings.
Our Marketing Manager, Esmeralda Zefi, had the pleasure of presenting the latest developments related to our device and our future projections. She shared how the project began in 2020 during the COVID-19 pandemic, driven by the needs of Spanish cardiologists. Their involvement has ensured that the project remains closely aligned with real-world clinical needs and effectively addresses key challenges in cardiac health.
A key takeaway from the round table was the confirmation that our work on new technologies is not only advancing but also proving to be highly innovative. We have developed the first device in the world capable of simultaneously capturing both the electrical and mechanical activity of the heart. Furthermore, Sensocor shows great potential for application in other pathologies, highlighting our commitment to improving patient outcomes in collaboration with hospitals.
Esmeralda also emphasized that, as a medical device company, we continue to face challenges that slow down the commercialization process. Strategic measures, such as advancing new technologies while navigating the CE Mark approval process, are essential to maintaining our momentum.
It was also highlighted that hospitals have been crucial throughout this process. Sensocor is currently being validated in ten hospitals across Spain. The only factor slowing down the process is the formal approval, as many hospitals both within and outside Spain have already shown strong interest in the device and its potential implementation.
Esmeralda further noted that devices like Sensocor have a promising future as they meet the needs of patients and significantly improve their quality of life. She pointed out that patients are becoming increasingly receptive to new technologies, particularly those that are user-friendly, non-invasive, and easy to use — all qualities that Sensocor embodies.
Thanks to a team of top-tier professionals with extensive experience in the sector, Sensocor is on track to be fully ready by 2025 — with both hardware and software fully developed, clinical trials ongoing across Spain, and preparations underway for both CE Mark and FDA approval. At the same time, we are setting the groundwork for our international commercialization strategy.
Comments